Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 19Breast Neoplasms 4Neoplasm Metastasis 3Thyroid Neoplasms 1Prostate Carcinoma Metastatic to the Bone 1Prostate Cancer Metastatic to Bone 1Prostate Adenocarcinoma 1Lung Neoplasms 1Hormone Refractory Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × radium Ra 223 dichloride × Clear all
NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Icahn School of Medicine at Mount Sinai

Phase 2 Completed
40 enrolled 18 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00337155 2023-11-02

BAY88-8223, Dose Finding Study in Patients With HRPC

Bayer

Phase 2 Completed
122 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00459654 2014-06-25

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Bayer

Phase 2 Completed
64 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡